Cwm LLC Reduces Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Cwm LLC lessened its stake in HealthEquity, Inc. (NASDAQ:HQY) by 8.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,635 shares of the company’s stock after selling 323 shares during the quarter. Cwm LLC’s holdings in HealthEquity were worth $298,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in shares of HealthEquity during the second quarter worth $35,000. Fidelis Capital Partners LLC acquired a new stake in HealthEquity during the 1st quarter valued at $42,000. GAMMA Investing LLC increased its stake in HealthEquity by 114.8% during the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after buying an additional 318 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in HealthEquity in the 2nd quarter worth $73,000. Finally, Headlands Technologies LLC acquired a new position in HealthEquity in the 1st quarter worth $130,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Buying and Selling at HealthEquity

In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the sale, the insider now directly owns 89,769 shares in the company, valued at approximately $7,168,952.34. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at $4,540,582.62. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,497 shares of company stock worth $3,579,769 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Bank of America lowered their price objective on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Barrington Research reaffirmed an “outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research report on Friday, September 20th. JMP Securities reissued a “market outperform” rating and set a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $103.83.

HealthEquity Stock Up 0.1 %

HQY stock opened at $87.74 on Tuesday. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 95.37, a PEG ratio of 1.31 and a beta of 0.52. HealthEquity, Inc. has a 1-year low of $61.81 and a 1-year high of $89.23. The firm has a fifty day moving average price of $79.11 and a two-hundred day moving average price of $79.51. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. Research analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current year.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.